Juno Therapeutics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Juno Therapeutics (JUNO) Misses Q3 EPS by 12c, Offers Guidance
November 10, 2015 4:07 PM ESTJuno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.53), $0.12 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.6 million, versus $0 reported last year.
2015 Financial Guidance
Juno continues to expect 2015 cash burn, excluding cash inflows or outflows from business... More
